Harold Clausen, MD
Interventional Cardiology · Baton Rouge, LANPI 1417958240
Payments from drug & device makers
Across 246 payments — averaging $22.00 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$1K
- Abiomed$874
- Irhythm Technologies, Inc.$390
- Merck$362
- Esperion Therapeutics, Inc.$302
- Novartis$219
- plus $2K from 25 others
What the payments were for
- Food & beverage$5,36899%
- Education$421%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen | 80 | $1,018 |
| Abiomed | 17 | $874 |
| Irhythm Technologies, Inc. | 27 | $390 |
| Merck | 21 | $362 |
| Esperion Therapeutics, Inc. | 12 | $302 |
| Novartis | 12 | $219 |
| Medtronic | 3 | $212 |
| Shockwave Medical, Inc | 3 | $209 |
| Johnson & Johnson | 8 | $199 |
| Scpharmaceuticals Inc. | 7 | $187 |
| E.r. Squibb & Sons, L.L.C. | 6 | $173 |
| Novo Nordisk | 3 | $152 |
| Amarin Pharma, Inc. | 5 | $146 |
| Pfizer | 8 | $129 |
| AstraZeneca | 7 | $114 |
| Cardiovascular Systems Inc. | 1 | $100 |
| Boehringer Ingelheim | 5 | $91 |
| Kestra Medical Technology Services, Inc. | 3 | $75 |
| W. L. Gore & Associates, Inc. | 1 | $67 |
| Baxter Healthcare | 1 | $49 |
| Abbott | 2 | $48 |
| Lexicon Pharmaceuticals, Inc. | 2 | $42 |
| Kiniksa Pharmaceuticals International, PLC | 2 | $39 |
| Itamar Medical Inc | 1 | $37 |
| Boston Scientific | 2 | $35 |
| Arbor Pharmaceuticals, Inc. | 2 | $35 |
| Impulse Dynamics (USA) Inc. | 1 | $28 |
| Alnylam Pharmaceuticals Inc. | 1 | $27 |
| Kowa Pharmaceuticals America, Inc. | 1 | $20 |
| Lilly USA, LLC | 1 | $17 |
| Azurity Pharmaceuticals, Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$5,411 in reported general payments places this provider in the 30th percentile of 171 interventional cardiology providers in Louisiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 813 | $680,467 |
| XareltoRivaroxaban | 329 | $290,498 |
| EntrestoSacubitril/Valsartan | 158 | $153,705 |
| Repatha SureclickEvolocumab | 106 | $124,276 |
| JardianceEmpagliflozin | 23 | $29,650 |
| VascepaIcosapent Ethyl | 43 | $26,691 |
| FarxigaDapagliflozin Propanediol | 30 | $21,775 |
| Praluent PenAlirocumab | 20 | $20,324 |
| Metoprolol Succinate | 1,004 | $11,157 |
| Ezetimibe | 589 | $10,643 |
| NexlizetBempedoic Acid/Ezetimibe | 16 | $9,969 |
| Atorvastatin Calcium | 818 | $8,682 |
| LivaloPitavastatin Calcium | 15 | $8,653 |
| Rosuvastatin Calcium | 690 | $7,816 |
| ClopidogrelClopidogrel Bisulfate | 631 | $6,610 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $129 | $680,467813 claims |
| Johnson & JohnsonXarelto | $199 | $290,498329 claims |
| NovartisEntresto | $219 | $153,705158 claims |
| Boehringer IngelheimJardiance | $91 | $29,65023 claims |
| AstraZenecaFarxiga, Brilinta | $114 | $27,93244 claims |
| Esperion Therapeutics, Inc.Nexlizet, Nexletol | $302 | $14,98528 claims |
| Kowa Pharmaceuticals America, Inc.Livalo | $20 | $8,65315 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 30th percentile of 171 interventional cardiology providers in Louisiana.
Other interventional cardiology in Baton Rouge
- Denzil MoraesBaton Rouge$1.4M
- Jorge CastellanosBaton Rouge$561K
- Venkata GadiBaton Rouge$132K
- Steven KelleyBaton Rouge$116K
- Andrew ReesBaton Rouge$95K
- Garland GreenBaton Rouge$37K
- Harold HelmkeBaton Rouge$32K
- Lance LamotteBaton Rouge$24K
- Craig WalkerHouma$5.5M
- Naseem JaffraniAlexandria$5.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.